This document is a publication of a European patent application (EP4504796A1) for binding molecules targeting human epidermal growth factor receptor 2. The patent application was filed by The National Institute for Biotechnology in the Negev Ltd. and lists Niv Papo and Lital Ben Naim as inventors. The publication date is March 18, 2026.

As this is a patent publication, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it may be relevant for pharmaceutical and biotechnology companies involved in research, development, or commercialization of therapies targeting EGFR2, particularly concerning intellectual property and market exclusivity.